| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 18/12/2024 | 22:30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 13/11/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 07/11/2024 | 13:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 07/11/2024 | 13:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 08/10/2024 | 22:01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 09/09/2024 | 13:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 07/08/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 10/06/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 16/05/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 07/05/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 07/05/2024 | 13:57 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 10/04/2024 | 13:00 | Business Wire | MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 10/04/2024 | 13:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 10/03/2024 | 17:00 | GlobeNewswire Inc. | MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 04/03/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 29/02/2024 | 14:05 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 29/02/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 26/02/2024 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 15/02/2024 | 22:02 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 15/02/2024 | 14:00 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 14/11/2023 | 14:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 05/11/2023 | 17:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 15/10/2023 | 15:03 | GlobeNewswire Inc. | MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 11/10/2023 | 16:15 | GlobeNewswire Inc. | MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 04/10/2023 | 13:01 | GlobeNewswire Inc. | Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 06/09/2023 | 13:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 10/08/2023 | 13:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 25/07/2023 | 14:00 | GlobeNewswire Inc. | MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 17/07/2023 | 13:30 | IH Market News | Monday’s Wall Street Highlights: Microsoft, Santander, Tesla, Chewy, and more | NASDAQ:MLTX | MoonLake Immunotherapeutics |
| 28/06/2023 | 11:00 | GlobeNewswire Inc. | MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares | NASDAQ:MLTX | MoonLake Immunotherapeutics |